Radboud UMC Nijmegen

Glycostem and Radboud UMC partnered in preclinical and clinical research.

During a four year project period Glycostem has successfully established the translation "from bench to bedside" of oNKord® together with collaborating partners at RadboudUMC in Nijmegen, the Netherlands. After an initial phase of preclinical research to improve treatment of AML, the technology has been successfully transferred into a phase I clinical trial to use NK cells in elderly patients in AML.